Q1 EPS Estimate for Beam Therapeutics Reduced by Analyst

Beam Therapeutics Inc. (NASDAQ:BEAM) – Wedbush dropped their Q1 2025 earnings per share estimates for shares of Beam Therapeutics in a note issued to investors on Tuesday, February 25th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings of ($1.21) per share for the quarter, down from their prior estimate of ($1.16). Wedbush has a “Outperform” rating and a $57.00 price target on the stock. The consensus estimate for Beam Therapeutics’ current full-year earnings is ($4.57) per share. Wedbush also issued estimates for Beam Therapeutics’ Q2 2025 earnings at ($1.18) EPS, Q3 2025 earnings at ($1.18) EPS, Q4 2025 earnings at ($1.24) EPS, FY2025 earnings at ($4.81) EPS, FY2026 earnings at ($5.60) EPS, FY2027 earnings at ($5.42) EPS and FY2028 earnings at ($4.15) EPS.

Several other analysts have also issued reports on the company. HC Wainwright reiterated a “buy” rating and issued a $80.00 price objective on shares of Beam Therapeutics in a research report on Monday, February 3rd. Leerink Partnrs upgraded Beam Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, November 6th. Sanford C. Bernstein upgraded Beam Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, January 7th. Leerink Partners upgraded Beam Therapeutics from a “market perform” rating to an “outperform” rating and boosted their price objective for the company from $27.00 to $39.00 in a research report on Wednesday, November 6th. Finally, Cantor Fitzgerald upgraded Beam Therapeutics from a “neutral” rating to an “overweight” rating in a research report on Wednesday, January 29th. Two analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $47.89.

Beam Therapeutics Price Performance

Shares of BEAM opened at $27.89 on Thursday. The firm has a market cap of $2.31 billion, a P/E ratio of -15.85 and a beta of 1.92. The stock has a 50 day simple moving average of $27.19 and a two-hundred day simple moving average of $25.89. Beam Therapeutics has a 1 year low of $20.84 and a 1 year high of $49.50.

Beam Therapeutics (NASDAQ:BEAM) last issued its quarterly earnings data on Tuesday, February 25th. The company reported ($1.09) EPS for the quarter, topping the consensus estimate of ($1.25) by $0.16. Beam Therapeutics had a negative return on equity of 16.22% and a negative net margin of 41.07%. The company had revenue of $30.00 million during the quarter, compared to analyst estimates of $16.47 million. During the same quarter in the previous year, the firm earned $1.73 earnings per share. Beam Therapeutics’s revenue was down 90.5% on a year-over-year basis.

Insiders Place Their Bets

In other news, CEO John M. Evans sold 30,000 shares of the stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $26.75, for a total value of $802,500.00. Following the sale, the chief executive officer now directly owns 908,659 shares of the company’s stock, valued at approximately $24,306,628.25. This represents a 3.20 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Christine Bellon sold 1,241 shares of the stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $24.68, for a total value of $30,627.88. Following the completion of the sale, the insider now directly owns 102,968 shares in the company, valued at approximately $2,541,250.24. This represents a 1.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.20% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Beam Therapeutics

A number of institutional investors have recently modified their holdings of BEAM. Wealthfront Advisers LLC purchased a new stake in shares of Beam Therapeutics during the fourth quarter valued at $41,000. GF Fund Management CO. LTD. purchased a new stake in shares of Beam Therapeutics during the fourth quarter valued at $43,000. Sterling Capital Management LLC boosted its position in shares of Beam Therapeutics by 816.0% during the fourth quarter. Sterling Capital Management LLC now owns 2,409 shares of the company’s stock valued at $60,000 after buying an additional 2,146 shares during the last quarter. Blue Trust Inc. boosted its position in shares of Beam Therapeutics by 84.0% during the third quarter. Blue Trust Inc. now owns 3,135 shares of the company’s stock valued at $73,000 after buying an additional 1,431 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Beam Therapeutics by 21.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,981 shares of the company’s stock valued at $75,000 after buying an additional 524 shares during the last quarter. 99.68% of the stock is owned by hedge funds and other institutional investors.

Beam Therapeutics Company Profile

Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.